HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
OTC Drugs US State News Legal Issues

Federal Preemption Strikes California Prop 65 Complaint Against Generic OTC Ranitidine Firms

Case Against Zantac Marketer Could Strike Out On Faulty Research Behind Carcinogen Claim

  • News

Executive Summary

Whether California court finds Zantac, when marketed containing ranitidine, should have had a Prop 65 label warning could be influenced by dismissal in federal court of class action complaints due to faulty research behind claims that ranitidine causes a carcinogenic substance to form post-production.

Table

View full table

Related Content

HBW Insight
HBW Insight
HBW Insight
HBW Insight
HBW Insight
HBW Insight

Topics

Related Companies

Tags:
OTC Drugs US State News Legal Issues
Latest Headlines

Supreme Court To Hear RICO Complaint Against CBD Firms As Hemp Regulation Remains AWOL

Nestlé Joins Forces With Dr Reddy’s In India To Grow Dietary Supplements Reach

Partisan Politics Returns To US FDA Congressional Oversight

The Aspirin Test For AI?

See All
UsernamePublicRestriction

Register

RS153490

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By